查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1924649

診斷放射性藥物市場（依產品類型、放射性核種、應用、最終用途及通路分類）－2026-2032年全球預測

Diagnostic Radiopharmaceuticals Market by Product Type, Radionuclide, Application, End Use, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，診斷放射性藥物市場價值將達到 32.8 億美元，到 2026 年將成長至 35.7 億美元，到 2032 年將達到 64 億美元，年複合成長率為 10.01%。

關鍵市場統計數據
基準年 2025 32.8億美元
預計年份：2026年 35.7億美元
預測年份 2032 64億美元
複合年成長率 (%) 10.01%

這是一份經營團隊和臨床醫生的策略指南，說明現代診斷放射性藥物、技術融合、臨床促進因素和營運重點。

隨著分子成像技術的進步、監管環境的日益清晰以及供應鏈的現代化，診斷放射性藥物產業正在迅速發展，並重塑臨床實踐。本導言為需要對當前產業環境及其即將到來的轉折點進行綜合性、循證理解的經營團隊、臨床醫生和投資者提供了清晰易懂的指導。它重點闡述了示踪劑創新、影像平台功能以及伴隨診斷在實現精準醫療中日益重要的作用之間的相互作用。

技術創新、監管政策的明確性以及營運整合如何共同改變分子影像示蹤劑的效用、臨床工作流程和商業化路徑

診斷放射性藥物領域正經歷一場變革浪潮，其驅動力來自技術創新、監管成熟和不斷變化的臨床需求。新型PET示蹤劑具有更高的特異性和更長的效用壽命，能夠更精確地表徵病灶並進行治療分層。同時，迴旋加速器的普及和發生器技術的同步進步正在提升醫療機構的自主生產能力。因此，投資於整合影像工作流程和放射化學專業知識的醫療機構更有能力縮短診斷時間，並充分發揮分子影像的臨床價值。

評估關稅帶來的成本壓力對2025年前營運和採購的影響，並探討各組織如何調整其採購、生產和庫存策略。

關稅的累積影響將持續到2025年，對診斷放射性藥物產業的生產和分銷經濟造成了顯著壓力。進口原料、專用組件和某些放射性核種產生器的關稅成本上漲，促使相關人員重新評估其籌資策略和庫存管理實務。為此，一些製造商盡可能在地採購，而另一些製造商則透過供應商多元化和重新談判供應合約來緩解利潤率下降。

詳細的細分分析揭示了產品類型、臨床應用、放射性核素特性、最終用途環境和分銷選擇如何影響採用趨勢和營運風險。

細分市場層面的洞察凸顯了臨床需求、生產複雜性和商業性機會在產品-應用-放射性核種-最終用途-通路等各個維度上的交匯點。在產品類型方面，PET和SPECT放射性藥物的差異決定了不同的研發路徑和物流需求。在PET放射性藥物中，碳-11、氟-18和鎵-68的半衰期和生產規模各不相同，這會影響它們在臨床應用方面的可行性。同時，在SPECT放射性藥物中，碘-123、Technetium-99m和鉈-201具有傳統的臨床應用價值和成熟的供應鏈，這影響著人們對這些放射性藥物的採納和替代風險的評估。

區域比較評估概述了關鍵區域的基礎設施、監管差異和分銷物流如何影響臨床應用和商業化方法。

區域趨勢受臨床能力、法規結構和供應鏈結構等因素的共同影響，進而影響診斷放射性藥物的地域覆蓋範圍和商業化進程。在美洲，完善的核子醫學基礎設施、密集的學術醫療中心以及較為寬鬆的支付環境，有利於新型示蹤劑的快速臨床應用。然而，區域報銷政策的差異和物流距離的差異，造成了營運上的細微差別，需要根據區域特徵制定相應的分銷和服務模式。

企業策略要務將示蹤劑創新、生產柔軟性和協作商業化模式結合，以確保臨床應用和持續的市場進入。

公司層級的考量主要集中在研發重點、製造地和商業夥伴關係方面的策略選擇將如何決定其競爭地位。主要企業正投資於示蹤劑研發管線，優先考慮臨床差異化、可重複的生產流程以及支援集中式和分散式供應模式的模組化生產能力。這些企業正將示踪劑的開發與強力的臨床證據生成和相關人員參與計劃相結合，以增強臨床效用並促進醫保報銷談判。

為加強生產韌性、臨床支援以及建立生態系統夥伴關係以推動應用並確保業務永續營運連續性，提出切實可行的建議

產業領導者應在控制成本的同時，優先考慮供應鏈韌性、臨床整合和實證醫學證據的產生。首先，擴大靈活的生產能力並實現原料和來源多元化，可以降低貿易中斷和關稅波動帶來的風險，並能夠快速回應不斷變化的臨床需求。其次，將示蹤劑的應用與切實可行的臨床支持項目（標準化的影像通訊協定、放射科醫生培訓以及強調臨床終點的醫保支付材料）相結合，可以加快示踪劑在臨床環境中的應用，並明確報銷流程。

一種透明、以證據為導向的調查方法，結合相關人員訪談、臨床文獻綜合和供應鏈營運分析，將策略洞見與實際情況結合。

本分析的調查方法結合了系統性文獻綜述、針對性相關人員訪談以及對臨床和營運證據的結構化綜合分析。主要定性資料來自對核子醫學醫師、放射性藥物藥劑師、供應鏈管理人員和監管專家的訪談，以確保能夠捕捉實際實施中的挑戰和臨床決策的決定因素。這些見解與同行評審文章、監管指導文件和行業技術簡報進行三角驗證，檢驗臨床結論並闡明營運限制。

透過整體整合，將示蹤劑創新、營運準備和策略商業化連結起來，以推動臨床影響和在醫療保健領域的永續應用。

總之，診斷放射性藥物處於科學進步與實際應用的交匯點，示蹤劑的創新必須與生產的靈活性、臨床教育和強大的分銷網路相輔相成。最成功的措施將預見物流限制，投資於嚴謹的臨床證據，並設計符合診斷影像中心、醫院和研究機構實際情況的商業化模式。監管政策的明確和數位成像技術的進步，加上確鑿的價值證明，將促進其進一步的規模化應用。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 診斷放射性藥物市場（依產品類型分類）

  • PET放射性藥物
  • SPECT放射性藥物

9. 依放射性核種類型分類的診斷放射性藥物市場

  • 氟-18
  • 鎵-68
  • 碘-123
  • Technetium-99m

第10章 按應用分類的診斷放射性藥物市場

  • 心臟病學
    • 灌注影像
    • 可行性成像
  • 神經病學
    • 阿茲海默症
    • 帕金森氏症
  • 腫瘤學
    • 乳癌
    • 肺癌
    • 攝護腺癌

第11章 以最終用途分類的診斷放射性藥物市場

  • 診斷影像中心
  • 醫院
  • 研究所

第12章 診斷放射性藥物市場（依分銷管道分類）

  • 離線
  • 線上

第13章 區域診斷放射性藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 診斷放射性藥物市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國診斷放射性藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國診斷放射性藥物市場

第17章：中國診斷放射性藥物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Actinium Pharmaceuticals Inc
  • Advanced Accelerator Applications SA
  • Bayer AG
  • Bracco Imaging SpA
  • BWXT Medical Ltd
  • Cardinal Health
  • China Isotope & Radiation Corporation
  • Clarity Pharmaceuticals Pty Ltd
  • Curium Pharma
  • Eckert & Ziegler AG
  • Eli Lilly and Company
  • GE Healthcare
  • Imagen Clinical Ltd
  • Isologic Innovative Radiopharmaceuticals Ltd
  • ITM Isotope Technologies Munich SE
  • Jubilant Pharmova Limited
  • Lantheus Holdings Inc
  • Nordion Inc
  • NorthStar Medical Radioisotopes LLC
  • Novartis AG
  • Oncoinvent AS
  • RadioMedix Inc
  • Radiopharm Theranostics Ltd
  • Siemens Healthineers
  • Telix Pharmaceuticals Ltd
Product Code: MRR-7A380DA7C3FA

The Diagnostic Radiopharmaceuticals Market was valued at USD 3.28 billion in 2025 and is projected to grow to USD 3.57 billion in 2026, with a CAGR of 10.01%, reaching USD 6.40 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.28 billion
Estimated Year [2026] USD 3.57 billion
Forecast Year [2032] USD 6.40 billion
CAGR (%) 10.01%

A strategic orientation to contemporary diagnostic radiopharmaceuticals that explains technological convergence, clinical drivers, and operational priorities for executives and clinicians

The diagnostic radiopharmaceuticals landscape is undergoing rapid evolution as advances in molecular imaging, regulatory clarity, and supply chain modernization converge to reshape clinical practice. This introduction provides a clear, accessible orientation for executives, clinicians, and investors who require an evidence-based synthesis of the current environment and its near-term inflection points. It highlights the interplay between tracer innovation, imaging platform capabilities, and the growing role of companion diagnostics in enabling precision medicine pathways.

Readers will find a concise framing of the technologies, clinical use-cases, and stakeholder incentives that drive demand for PET and SPECT agents across diagnostic applications. The narrative emphasizes practical considerations such as production logistics, radionuclide half-life management, and integration with imaging infrastructure, while drawing attention to regulatory and reimbursement factors that influence adoption trajectories. By establishing this baseline, the introduction sets the stage for deeper analysis of structural shifts, tariff-driven cost dynamics, and segment-specific strategic implications.

How technological innovation, regulatory clarity, and operational integration are jointly transforming tracer utility, clinical workflows, and commercialization pathways in molecular imaging

The field of diagnostic radiopharmaceuticals is experiencing transformative shifts driven by confluence of technological innovation, regulatory maturation, and changing clinical demand. Novel PET tracers with improved specificity and longer utility windows are enabling more precise lesion characterization and treatment stratification, while parallel improvements in cyclotron access and generator technologies are expanding on-site production capabilities. Consequently, institutions that invest in integrated imaging workflows and radiochemistry expertise are positioned to shorten time-to-diagnosis and to capture the clinical value of molecular imaging.

Regulatory agencies are increasingly providing clearer pathways for tracer approval and for companion diagnostic claims, which reduces procedural ambiguity for sponsors and accelerates clinical translation. Meanwhile, digital imaging analytics and AI-driven quantification enhance interpretive consistency and permit more efficient utilization of imaging assets. Taken together, these dynamics are reshaping procurement priorities, clinical protocols, and partnership models across suppliers, academic centers, and diagnostic networks, and they highlight the need for iterative alignment between product development and health-system operational readiness.

Assessing the operational and procurement implications of tariff-driven cost pressures through 2025 and how organizations are adapting sourcing, production, and inventory strategies

The cumulative effects of tariff actions enacted through 2025 have introduced measurable pressure on manufacturing and distribution economics within the diagnostic radiopharmaceutical sector. Tariff-induced cost increases for imported raw materials, specialized components, and select radionuclide generators have encouraged stakeholders to re-evaluate sourcing strategies and inventory practices. In response, some manufacturers have localized critical inputs where feasible, while others have pursued supplier diversification and renegotiated supply contracts to mitigate margin compression.

Across clinical providers, elevated input costs have driven more disciplined purchasing and an increased focus on operational efficiency, including dose optimization and scheduling strategies that reduce waste from short-lived isotopes. Regulatory compliance and cold-chain integrity remain non-negotiable, so organizations have balanced cost containment with the need to preserve quality and patient safety. Importantly, tariff impacts have also accelerated conversations around domestic production capacity and public-private partnerships that can reduce exposure to cross-border trade variability. Looking forward, institutions will likely continue to adapt procurement models and contractual structures to enhance resilience amid evolving trade policy landscapes.

Deep segmentation analysis revealing how product type, clinical application, radionuclide profile, end-use setting, and distribution choices shape adoption dynamics and operational risks

Segment-level insights clarify where clinical demand, production complexity, and commercial opportunity intersect across product, application, radionuclide, end-use, and distribution vectors. Based on Product Type, the distinction between PET Radiopharmaceuticals and SPECT Radiopharmaceuticals frames divergent development pathways and logistical requirements; within PET Radiopharmaceuticals, Carbon-11, Fluorine-18, and Gallium-68 represent varying half-lives and production footprints that influence site-of-care feasibility, while within SPECT Radiopharmaceuticals, Iodine-123, Technetium-99m, and Thallium-201 carry legacy clinical roles and established supply chains that inform adoption and substitution risks.

Based on Application, clinical segmentation across Cardiology, Neurology, and Oncology highlights differing clinical workflows and payer dynamics; cardiology use-cases such as Perfusion Imaging and Viability Imaging require high-throughput protocols and rapid tracer availability, neurology indications focused on Alzheimer's and Parkinson's necessitate high specificity and longitudinal imaging consistency, and oncology applications across Breast Cancer, Lung Cancer, and Prostate Cancer demand tracers that support staging, recurrence detection, and therapy selection. Based on Radionuclide, the prominence of Fluorine-18, Gallium-68, Iodine-123, and Technetium-99m delineates supply chain and half-life management priorities. Based on End Use, Diagnostic Imaging Centers, Hospitals, and Research Institutes each exhibit distinct capital investment profiles and regulatory oversight that shape adoption timing and partnership opportunities. Based on Distribution Channel, Direct Sales, Distributors, and Online Channels create different customer engagement models and service-level expectations, which in turn influence margin structures and post-sale support requirements.

These layered segmentations underscore the necessity of aligning product development with practical constraints such as isotopic half-life, on-site production capacity, and clinical throughput. Consequently, organizations with adaptable manufacturing, robust distribution agreements, and clinical support services are best positioned to capitalize on cross-segment synergies while managing operational complexity.

Comparative regional assessment that outlines how infrastructure, regulatory diversity, and distribution logistics shape clinical uptake and commercialization approaches across key territories

Regional dynamics reflect a combination of clinical capacity, regulatory frameworks, and supply chain architecture that influence where diagnostic radiopharmaceuticals gain traction and how they are commercialized. In the Americas, established nuclear medicine infrastructure, a concentration of academic medical centers, and a receptive payer environment support rapid clinical translation of novel tracers, but regional reimbursement variability and logistical distances present operational nuances that require tailored distribution and service models.

In Europe, Middle East & Africa, heterogeneous regulatory regimes and varied healthcare financing mechanisms necessitate a regionally nuanced go-to-market strategy that accounts for national certification frameworks and differing levels of cyclotron access, while collaborative cross-border research and consortium-based procurement offer pathways to scale. In Asia-Pacific, rapid investment in diagnostic imaging capacity, growing oncology care demand, and expanding manufacturing capabilities have created fertile conditions for both local production and international partnerships, although procurement processes and regulatory timelines vary widely between markets. Across all regions, proximity to production sites, robustness of cold-chain logistics, and clinician familiarity with novel tracers will determine the pace and pattern of clinical adoption, underscoring the importance of region-specific commercialization plans that reflect local operational realities.

Strategic company imperatives that align tracer innovation, production flexibility, and collaborative commercialization models to secure clinical adoption and durable market access

Company-level considerations focus on how strategic choices in R&D focus, manufacturing footprint, and commercial partnerships determine competitive positioning. Leading organizations are investing in tracer pipelines that prioritize clinical differentiation, reproducible manufacturing processes, and modular production capacity to support both centralized and decentralized supply models. These firms are coupling tracer development with robust clinical evidence generation and stakeholder engagement programs to reinforce clinical utility and to smooth reimbursement dialogues.

Across the ecosystem, smaller specialized players are leveraging nimble development cycles and targeted clinical collaborations to establish early clinical proof points, while larger diversified suppliers are integrating radiopharmaceuticals into broader diagnostic portfolios and leveraging global distribution networks. Strategic alliances between manufacturers, imaging equipment providers, and clinical research organizations are also becoming more common as firms seek to lower barriers to adoption through bundled solutions that address tracer availability, imaging protocols, and interpretive support. Ultimately, companies that balance scientific rigor with pragmatic operational solutions and proactive regulatory engagement will achieve the most durable market access and clinical integration.

Actionable recommendations for bolstering production resilience, clinical support, and ecosystem partnerships to accelerate adoption and safeguard operational continuity

Industry leaders should prioritize investments that strengthen supply chain resilience, clinical integration, and evidence generation while maintaining cost discipline. First, expanding flexible production capacity and diversifying raw material and generator sourcing reduces exposure to trade disruptions and tariff volatility, and it enables faster response to clinical demand shifts. Second, coupling tracer launches with pragmatic clinical support programs-standardized imaging protocols, education for interpreting physicians, and payer-facing dossiers that emphasize clinical endpoints-will accelerate institutional uptake and reimbursement clarity.

Third, forging partnerships across the imaging ecosystem, including imaging device manufacturers, research hospitals, and specialty distributors, will facilitate bundled proposition development that reduces the operational burden on adopters. Fourth, leaders should adopt digital and AI-enabled tools to improve quantitative imaging reproducibility and to extract real-world evidence from routine clinical use; such data strengthen value propositions and support iterative improvements. Finally, organizations should adopt a modular commercialization approach that customizes distribution and service models for Diagnostic Imaging Centers, Hospitals, and Research Institutes, thereby aligning price, service, and compliance expectations with end-user capabilities and procurement preferences.

Transparent, evidence-focused methodology combining stakeholder interviews, clinical literature synthesis, and operational supply chain analysis to ground strategic insights in practical realities

The methodology underpinning this analysis combined systematic literature review, targeted stakeholder interviews, and a structured synthesis of clinical and operational evidence. Primary qualitative inputs were drawn from interviews with practicing nuclear medicine physicians, radiopharmacists, supply chain managers, and regulatory specialists, ensuring that practical implementation challenges and clinical decision drivers were captured. These perspectives were triangulated with peer-reviewed publications, regulatory guidance documents, and industry technical briefs to validate clinical claims and to contextualize operational constraints.

Analysts applied a cross-sectional lens to segment performance, mapping tracer attributes-such as radionuclide half-life, synthesis complexity, and imaging protocol requirements-to end-user capabilities and distribution modalities. Where appropriate, supply chain analyses examined manufacturing footprints, generator and cyclotron dependencies, and cold-chain requirements to assess operational feasibility. Throughout, the approach favored transparency in assumptions and prioritized evidence that directly informs clinical utility, regulatory readiness, and operational execution.

Concluding synthesis that links tracer innovation, operational readiness, and strategic commercialization to drive clinical impact and sustainable adoption across care settings

In conclusion, diagnostic radiopharmaceuticals stand at the intersection of scientific progress and operational pragmatism, where tracer innovation must be matched by production agility, clinical education, and resilient distribution. The most successful initiatives will be those that anticipate logistical constraints, invest in rigorous clinical evidence, and design commercialization models that align with the realities of Diagnostic Imaging Centers, Hospitals, and Research Institutes. Regulatory clarity and digital imaging advances will further enable scalable adoption when linked to robust value demonstrations.

As institutions and suppliers adapt to tariff pressures, evolving procurement practices, and region-specific considerations, strategic emphasis on supply diversification, clinical support services, and collaborative commercialization will determine how rapidly novel tracers translate into improved diagnostic pathways. Stakeholders who integrate these considerations into product development and market entry strategies will be better equipped to deliver clinical impact while managing operational and commercial risk.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Diagnostic Radiopharmaceuticals Market, by Product Type

  • 8.1. PET Radiopharmaceuticals
  • 8.2. SPECT Radiopharmaceuticals

9. Diagnostic Radiopharmaceuticals Market, by Radionuclide

  • 9.1. Fluorine-18
  • 9.2. Gallium-68
  • 9.3. Iodine-123
  • 9.4. Technetium-99m

10. Diagnostic Radiopharmaceuticals Market, by Application

  • 10.1. Cardiology
    • 10.1.1. Perfusion Imaging
    • 10.1.2. Viability Imaging
  • 10.2. Neurology
    • 10.2.1. Alzheimer's
    • 10.2.2. Parkinson's
  • 10.3. Oncology
    • 10.3.1. Breast Cancer
    • 10.3.2. Lung Cancer
    • 10.3.3. Prostate Cancer

11. Diagnostic Radiopharmaceuticals Market, by End Use

  • 11.1. Diagnostic Imaging Centers
  • 11.2. Hospitals
  • 11.3. Research Institutes

12. Diagnostic Radiopharmaceuticals Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Diagnostic Radiopharmaceuticals Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Diagnostic Radiopharmaceuticals Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Diagnostic Radiopharmaceuticals Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Diagnostic Radiopharmaceuticals Market

17. China Diagnostic Radiopharmaceuticals Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Actinium Pharmaceuticals Inc
  • 18.6. Advanced Accelerator Applications SA
  • 18.7. Bayer AG
  • 18.8. Bracco Imaging S.p.A.
  • 18.9. BWXT Medical Ltd
  • 18.10. Cardinal Health
  • 18.11. China Isotope & Radiation Corporation
  • 18.12. Clarity Pharmaceuticals Pty Ltd
  • 18.13. Curium Pharma
  • 18.14. Eckert & Ziegler AG
  • 18.15. Eli Lilly and Company
  • 18.16. GE Healthcare
  • 18.17. Imagen Clinical Ltd
  • 18.18. Isologic Innovative Radiopharmaceuticals Ltd
  • 18.19. ITM Isotope Technologies Munich SE
  • 18.20. Jubilant Pharmova Limited
  • 18.21. Lantheus Holdings Inc
  • 18.22. Nordion Inc
  • 18.23. NorthStar Medical Radioisotopes LLC
  • 18.24. Novartis AG
  • 18.25. Oncoinvent AS
  • 18.26. RadioMedix Inc
  • 18.27. Radiopharm Theranostics Ltd
  • 18.28. Siemens Healthineers
  • 18.29. Telix Pharmaceuticals Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PET RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY SPECT RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE-18, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE-18, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY FLUORINE-18, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY GALLIUM-68, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY GALLIUM-68, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY GALLIUM-68, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY IODINE-123, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY IODINE-123, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY IODINE-123, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM-99M, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM-99M, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY TECHNETIUM-99M, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PERFUSION IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PERFUSION IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PERFUSION IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY VIABILITY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY VIABILITY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY VIABILITY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ALZHEIMER'S, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ALZHEIMER'S, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ALZHEIMER'S, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PARKINSON'S, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PARKINSON'S, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PARKINSON'S, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. GCC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 159. GCC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. GCC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. GCC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. GCC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. G7 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 186. G7 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. G7 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. G7 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. G7 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. NATO DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 195. NATO DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. NATO DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. NATO DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. NATO DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 200. NATO DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY RADIONUCLIDE, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY NEUROLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)